u/BobMcPhil · 42d agono track record yet
Short BSX
Continue to Short Boston Scientific (BSX)
WATCHMAN, BSX's flagship LAAO device representing 10% of revenue, failed non-inferiority trials against anticoagulation therapy alone. The worse clinical outcomes and procedural risk will lead to de-prescription, materially damaging the company's revenue and profitability.
At post $45.05Now $45.69+1.4% since postedas of Oct 23, 4:45 PM ET
1d-2.6%
3d-3.3%
1w-3.0%
1m-4.6%
3m—
6m—
1y—